![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 1, 2024
Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of research findings at the 2024 ASCO Annual Meeting
May 1, 2024
Summaries of recently published ECOG-ACRIN research results
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
June 30, 2023
At a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
June 30, 2023
Researchers presented numerous research abstracts and trial updates at the 2023 ASCO Annual Meeting
April 19, 2023
Summaries of recently published ECOG-ACRIN research results
February 10, 2023
The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy
February 10, 2023
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma
October 13, 2022
Summaries of recently published ECOG-ACRIN research results